Bristol-myers Squibb Compnay

Ji Jiang

Heather J Finlay

James A Johnson

Jennifer X Qiao

Tammy C Wang

John E Lloyd

Zulan Pi

R Michael Lawrence

Soong-Hoon Kim

George O Tora

Carol Hui Hu

Wu Yang

Mark E Salvati

Yufeng Wang

Michael Matthew Miller

Lalgudi S Harikrishnan

Muthoni G Kamau

Jon J Hangeland

Jacques Y Roberge

Todd J Friends

James Neels

Richard A Rampulla

Wei Meng

Bang-Chi Chen

Cullen L Cavallaro

Prashantha Gunaga

Hannguang J Chao

Michael C Myers

Abhisek Banerjee

Naveen Kumar Dhondi

Jianqing Li

Brandon Lee Parkhurst

Monique Phillips

Lynn Abell

Leonard Adam

Ying Wang

Gang Wu

Jianxin Feng

Ashokkumar Adisechan

Ashok Kumar Adisechan

Michael R Lawrence

Joseph E Carpenter

The present invention provides compounds of Formula (I), or stereoisomers, tautomers, or pharmaceutically acceptable salts or solvates thereof, wherein all the variables are as defined herein. These compounds modulate the activity of farnesoid X receptor (FXR), for example, as agonists. This invention also relates to pharmaceutical compositions comprising these compounds and methods of treating a disease, disorder, or condition associated with FXR dysregulation, such as pathological fibrosis, transplant rejection, cancer, osteoporosis, and inflammatory disorders, by using the compounds and pharmaceutical compositions. 

Multicyclic compounds as farnesoid X receptor modulators

The present invention provides compounds of Formula (I) wherein all variables are as defined in the specification, and compositions comprising any of such novel compounds. These compounds are APJ agonists which may be used as medicaments. 

4-hydroxy-3-sulfonylpyridin-2(1H)-ones as APJ receptor agonists

The present invention provides compounds of Formula (I): wherein all variables are as defined in the specification, and compositions comprising any of such novel compounds. These compounds are APJ agonists which may be used as medicaments. 

2,4-dihydroxy-nicotinamides as APJ agonists

The present invention provides compounds of Formula (I) as defined in the specification and compositions comprising any of such novel compounds. These compounds are endothelial lipase inhibitors which may be used medicaments. 

Sulfone amide linked benzothiazole inhibitors of endothelial lipase

The present invention provides compounds of Formula (I): wherein all variables are as defined in the specification, and compositions comprising any of such novel compounds. These compounds are APJ agonists which may be used as medicaments.

4-hydroxy-3-(heteroaryl)pyridine-2-one APJ agonists

The present invention provides compounds of Formula (I): (I), as defined in the specification and compositions comprising any of such novel compounds. These compounds are endothelial lipase inhibitors which may be used as medicaments. 

Pyrrolinone carboxamide compounds useful as endothelial lipase inhibitors

A compound of formula I wherein A, X, Y, Z, Rand Rare described herein. The compounds are useful as inhibitors of potassium channel function and in the treatment and prevention of arrhythmia, I-associated disorders, and other disorders mediated by ion channel function.

Quinazolines as potassium ion channel inhibitors

The present invention provides compounds of Formula (I): as defined in the specification and compositions comprising any of such novel compounds. These compounds are endothelial lipase inhibitors which may be used as medicaments. The disclosure also provides a novel method of treating diseases or conditions related to the activity of endothelial lipase by use of compounds according to Formula (II): as defined in the specification and compositions comprising any of the compounds. 

The present invention provides compounds of Formula (I), as defined in the specification and compositions comprising any of such novel compounds. These compounds are endothelial lipase inhibitors which may be used as medicaments. 

Pyrimidinone carboxamide inhibitors of endothelial lipase

The present invention provides compounds of Formula (I): as defined in the specification and compositions comprising any of such novel compounds. These compounds are endothelial lipase inhibitors which may be used as medicament.

Ketone linked benzothiazole inhibitors of endothelial lipase

The present invention provides compounds of Formula (I): as defined in the specification and compositions comprising any of such novel compounds. These compounds are endothelial lipase inhibitors which may be used as medicaments.

Amide, urea or sulfone amide linked benzothiazole inhibitors of endothelial lipase

The present invention provides compounds of Formula (I) or Formula (III): [INSERT CHEMICAL STRUCTURE HERE] (I) [INSERT CHEMICAL STRUCTURE HERE] (III) as defined in the specification and compositions comprising any of such novel compounds. These compounds are endothelial lipase inhibitors which may be used as medicaments. 

Sulfonyl containing benzothiazole inhibitors of endothelial lipase

Compounds of formula Ia and Ib wherein A, B, C and Rare described herein.

Heterocyclic CETP inhibitors

A compound of formula (I) wherein A, X, Y, Z, Rand Rare described herein. The compounds are useful as inhibitors of potassium channel function and in the treatment and prevention of arrhythmia, I-associated disorders, and other disorders mediated by ion channel function. 

Growing community of inventors

West Windsor, NJ, United States of America

Ji Jiang